FAST NEWS: Sihuan Pharma turns red, but medical aesthetic business improves
The latest: Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) announced Wednesday it expects to record a loss before tax of no more than 40 million yuan ($5.6 million) from continuing operations in the…
Product Approval Breathes New Life Into Boan Biotech IPO
The biosimilar drug maker was approved to sell its second new product in China last month as it applies to list in Hong KongKey Takeaways:Boan Biotechnology has filed for a…
Lepu ScienTech Revives IPO After Policy Move Brightens Its Prospects
China’s leading supplier of congenital heart disease devices made its third filing earlier this month for a Hong Kong IPO Key Takeaways: After taking its Lepu Biopharma unit public in…
RELATED ARTICLES
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK -
FAST NEWS: Sihuan Pharma stock skyrockets on latest share buyback program
0460.HK
- SATP tallies up solid growth, thinning red ink in Hong Kong IPO application
-
So-Young dolls up with pivot to high-end services
SY.US
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
